Read by QxMD icon Read

annals of oncology

Mary Hayes, Erica Bloomquist, Heather Wright
The Editors of Annals of Surgical Oncology have retracted the following poster session abstract following an investigation by the authors' institution, which found that the study was not submitted to the IRB for approval.
April 20, 2018: Annals of Surgical Oncology
Ümran Muslu
OBJECTIVE: This study aims to make a bibliometric analysis of the studies on breast reduction (BR) between the years 1980 and 2016 and identify important studies through trend topics as well as active authors, countries, universities, scientific journals, and citation and co-citation analyses about BR. BACKGROUND: Although BR looks like one of the cosmetic surgeries performed in order to restore the woman's appearance, in fact it is a reconstructive surgery that eliminates back pain, stance disorder, headache, shoulder pain, back and cervical disk hernia, difficulty in breathing, hollowness caused by bra straps, hygiene problems under breasts (e...
January 19, 2018: Aesthetic Plastic Surgery
Julien Langrand-Escure, Romain Rivoirard, Mathieu Oriol, Fabien Tinquaut, Chloé Rancoule, Frank Chauvin, Nicolas Magné, Aurélie Bourmaud
BACKGROUND: Phase II clinical trials are a cornerstone of the development in experimental treatments They work as a "filter" for phase III trials confirmation. Surprisingly the attrition ratio in Phase III trials in oncology is significantly higher than in any other medical specialty. This suggests phase II trials in oncology fail to achieve their goal. Objective The present study aims at estimating the quality of reporting in published oncology phase II clinical trials. DATA SOURCES: A literature review was conducted among all phase II and phase II/III clinical trials published during a 5-year period (2010-2015)...
2017: PloS One
Charles M Balch, Mark Roh, Kelly M McMasters, Deborah Whippen
No abstract text is available yet for this article.
January 2018: Annals of Surgical Oncology
Charles M Balch, Mark S Roh, Colleen M Hubona
No abstract text is available yet for this article.
January 2018: Annals of Surgical Oncology
Charles Balch
No abstract text is available yet for this article.
January 2018: Annals of Surgical Oncology
Mark Roh, Deborah Whippen, Charles Balch
No abstract text is available yet for this article.
November 22, 2017: Annals of Surgical Oncology
F André
No abstract text is available yet for this article.
January 1, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
J-C Soria
No abstract text is available yet for this article.
October 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Hugues Duffau
Hugues Duffau is a Professor and Chairman of the Neurosurgery Department in the Montpellier University Medical Center and Head of the INSERM 1051 Team "plasticity of the central nervous system, human stem cells and glial tumors" at the Institute for Neurosciences of Montpellier (France). He is an expert in the awake cognitive neurosurgery of slow-growing brain tumors, such as low-grade gliomas, a routine which he has developed since 20 years. His fundamental approach is centered on the concepts of the brain connectomics and neuroplasticity, breaking with the traditional localizationist view of cerebral processing...
July 18, 2017: CNS Oncology
Romain Rivoirard, Vianney Duplay, Mathieu Oriol, Fabien Tinquaut, Franck Chauvin, Nicolas Magne, Aurelie Bourmaud
BACKGROUND: Quality of reporting for Randomized Clinical Trials (RCTs) in oncology was analyzed in several systematic reviews, but, in this setting, there is paucity of data for the outcomes definitions and consistency of reporting for statistical tests in RCTs and Observational Studies (OBS). The objective of this review was to describe those two reporting aspects, for OBS and RCTs in oncology. METHODS: From a list of 19 medical journals, three were retained for analysis, after a random selection: British Medical Journal (BMJ), Annals of Oncology (AoO) and British Journal of Cancer (BJC)...
2016: PloS One
Paola Queirolo, Francesco Spagnolo
Immunotherapy with anti-CTLA-4 and anti-PD-1 monoclonal antibodies is a breakthrough in the treatment of advanced cancer. The progressively broader indications of such drugs highlights the need of developing algorithms for the management of immune-related toxicities, as some adverse events may cause sequelae and even death if not managed effectively. Thanks to the collaboration of different specialist from the Gustave Roussy Institute in Paris, guidelines for the management of toxicities during treatment with immune checkpoint inhibitors were recently published on the journal Annals of Oncology...
August 2016: Recenti Progressi in Medicina
Charles M Balch, V Suzanne Klimberg, Kelly M McMasters, Timothy M Pawlik, Kenneth K Tanabe, Mitchell C Posner, Deborah Whippen, Mark S Roh
No abstract text is available yet for this article.
September 2016: Annals of Surgical Oncology
Pedro Cabrales, Jan Scicinski, Tony Reid, Frans Kuypers, Sandra Larkin, Marcel Fens, Arnold Oronsky, Bryan Oronsky
The therapeutic potential of epi-immunotherapeutic anticancer agent RRx-001 in cancer has been validated with preclinical and clinical studies, since RRx-001 has successfully completed a phase 1 trial and multiple single-agent and combination phase 2 trials with preliminary evidence of promising activity are underway. Previous experimental work has implicated diverse anticancer mechanisms such as oxidative stress, ATP and NADPH depletion, anti-angiogenesis and epigenetic modulation in the overall antitumor effect of RRx-001...
July 2016: Medical Oncology
C Thomas, M Bögemann, F König, S Machtens, M Schostak, T Steuber, A Heidenreich
In March 2015, the first Advanced Prostate Cancer Consensus Conference (APCC) took place in St. Gallen. 41 experts from 17 countries reviewed important areas of controversy in advanced hormone-naive and castration-resistant prostate cancer and gave therapy recommendations. These results have been recently published in "Annals of Oncology". While most of the recommendations from St. Gallen are comprehensible, some of them need to be further discussed. Therefore, we as a German expert panel will critically debate the St...
June 2016: Der Urologe. Ausg. A
John Souglakos
A combination of cytotoxic agents with cis-platin remains the cornerstone of treatment for the vast majority of patients with non-small cell lung cancer (NSCLC). Molecular analysis of the primary may lead better prognostication and eventually in more accurate therapeutic approaches. Data from retrospective analysis of randomized trials as well as large patients' series have suggested that chemotherapy may be customized upon molecular-genetic analysis of the tumor cells. The Spanish Lung Cancer Group (SLCG) in collaboration with French lung Cancer Group (FLCG) had conduct randomized, phase III, biomarkers-driven trial and supported simultaneously a randomized phase II trial in collaborating centers in China...
October 2015: Translational Lung Cancer Research
J-C Soria
No abstract text is available yet for this article.
January 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Anastasia Ivanova, Barry Paul, Olga Marchenko, Guochen Song, Neerali Patel, Stergios J Moschos
We investigated nine-year trends in statistical design and other features of Phase II oncology clinical trials published in 2005, 2010, and 2014 in five leading oncology journals: Cancer, Clinical Cancer Research, Journal of Clinical Oncology, Annals of Oncology, and Lancet Oncology. The features analyzed included cancer type, multicenter vs. single-institution, statistical design, primary endpoint, number of treatment arms, number of patients per treatment arm, whether or not statistical methods were well described, whether the drug was found effective based on rigorous statistical testing of the null hypothesis, and whether the drug was recommended for future studies...
2016: Journal of Biopharmaceutical Statistics
Emma B Holliday, Awad A Ahmed, Stella K Yoo, Reshma Jagsi, Karen E Hoffman
PURPOSE: Quality cancer care is best delivered through a multidisciplinary approach requiring awareness of current evidence for all oncologic specialties. The highest impact journals often disseminate such information, so the distribution and characteristics of oncology studies by primary intervention (local therapies, systemic therapies, and targeted agents) were evaluated in 10 high-impact journals over a 20-year period. METHODS AND MATERIALS: Articles published in 1994, 2004, and 2014 in New England Journal of Medicine, Lancet, Journal of the American Medical Association, Lancet Oncology, Journal of Clinical Oncology, Annals of Oncology, Radiotherapy and Oncology, International Journal of Radiation Oncology, Biology, Physics, Annals of Surgical Oncology, and European Journal of Surgical Oncology were identified...
July 15, 2015: International Journal of Radiation Oncology, Biology, Physics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"